Is carac affected by genetics?
Yes. Its active ingredient has published pharmacogenetic guidance for a gene that varies between people.
carac is affected by pharmacogenetics through the DPYD gene. Your genotype for this gene can change how well carac works for you or how well you tolerate it. The strongest evidence level on this page is Strong, from the published guidelines shown below.
What's in carac
Fluorouracil Affected by DPYD
Affected by DPYD. Guidance from CPIC, FDA, strong evidence.
Read the full fluorouracil genetics guideFluorouracil phenotype recommendations
Published guidance from CPIC and FDA on how fluorouracil should be dosed or substituted based on your DPYD phenotype.
| Phenotype | What it means | Recommendation | Evidence |
|---|---|---|---|
| Normal MetabolizerDPYD | Your body breaks down this drug normally. Your risk of side effects is typical, and the usual dose is used. | CPIC Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration FDA Initiate therapy with recommended starting dose. |
Strong |
| Intermediate MetabolizerDPYD | Your body breaks down this drug more slowly, which raises the risk of severe side effects. Doctors usually start at half the usual dose and adjust from there. | CPIC + CPIC Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.[2846A>T];[2846A>T] genotype may require >50% reduction in starting dose. FDA Insufficient data to recommend a dosage. Withhold or discontinue for early-onset or unusually severe toxicity. |
Strong |
| Poor MetabolizerDPYD | Your body breaks down very little of this drug, which can cause severe or even deadly side effects. Doctors usually avoid it or use a much lower dose. | CPIC + CPIC Activity score 0.5: Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring. Activity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. FDA No dosage has proven safe. |
Strong |
| IndeterminateDPYD | The impact of your genotype on response to this drug is unknown | CPIC + FDA Initiate therapy with recommended starting dose. |
Not rated |
| Not availableDPYD | The impact of your genotype on response to this drug is unknown | CPIC + FDA Initiate therapy with recommended starting dose. |
Not rated |
The gene behind the guidance
DPYD Dihydropyrimidine Dehydrogenase
DPYD breaks down fluoropyrimidine chemotherapy drugs (5-FU, capecitabine). A small percentage of people carry reduced-function variants that cause the drug to accumulate to toxic levels. The FDA labels for capecitabine and fluorouracil advise testing for DPYD variants before treatment starts.
CPIC recommends a 50 percent lower starting dose for intermediate metabolizers, adjusted to how the drug is tolerated, and avoiding these drugs for poor metabolizers, in whom standard doses can be fatal.
See all drugs affected by DPYDBrowse the full drug class: Chemotherapy agents.
Related medications
Find out how your genetics affect carac
Informational only, not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.